Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 73 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid TumorsCompletedNCT03312842Phase 1
- Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCsStatus unknownNCT03311789Phase 1/2
- T-Cell PET Imaging With [18F]F-AraG in Lung CancerWithdrawnNCT03311672Phase 2
- Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or LymphomasCompletedNCT03311412Phase 1
- A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial CarcinomaWithdrawnNCT03310567Phase 2
- Study of Durvalumab and Guadecitabine in Advanced Kidney CancerActive, not recruitingNCT03308396Phase 1/2
- Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryActive, not recruitingNCT03307616Phase 2
- Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCLCompletedNCT03305445Phase 1
- Immunotherapy by Nivolumab for HIV+ PatientsCompletedNCT03304093Phase 2
- The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001CompletedNCT03301688Phase 1
- Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)CompletedNCT03299946Phase 1
- Avelumab With Chemoradiation in Locally Advanced Rectal CancerCompletedNCT03299660Phase 2
- Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)CompletedNCT03298893Phase 1/2
- Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03297593Phase 2
- Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic MelanomaWithdrawnNCT03297463Phase 1/2
- Ribociclib + PDR001 in Breast Cancer and Ovarian CancerTerminatedNCT03294694Phase 1
- ASCT With Nivolumab in Patients With Multiple MyelomaActive, not recruitingNCT03292263Phase 1/2
- Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedNCT03292250Phase 2
- Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid LeukemiaWithdrawnNCT03291353Early Phase 1
- Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent GlioblastomaCompletedNCT03291314Phase 2
- A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT03289962Phase 1
- Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBCCompletedNCT03289819Phase 2
- Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)Status unknownNCT03288870Phase 2/3
- LZM009 to Treat Patients With Advanced Solid TumorsCompletedNCT03286296Phase 1
- PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.Status unknownNCT03283943Phase 1
- Immunotherapy and SBRT for Metastatic Head and Neck CarcinomasCompletedNCT03283605Phase 1/2
- Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1
- Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboActive, not recruitingNCT03281954Phase 3
- Denosumab and Pembrolizumab in Clear Cell Renal CarcinomaStatus unknownNCT03280667Phase 2
- Avelumab in G3 NECCompletedNCT03278405Phase 1/2
- Avelumab in G2-3 NETCompletedNCT03278379Phase 2
- Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasCompletedNCT03277924Phase 1/2
- Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)CompletedNCT03277638Phase 1/2
- Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerTerminatedNCT03277482Phase 1
- Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory LymphomasCompletedNCT03276468Phase 2
- Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial CancerCompletedNCT03276013Phase 2
- Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint InhibitionTerminatedNCT03275597Phase 1
- Adjuvant Avelumab in Merkel Cell CancerActive, not recruitingNCT03271372Phase 3
- International Trial of the Efficacy and Safety of BCD-100 in Patients With MelanomaStatus unknownNCT03269565Phase 2
- Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory MeningiomaTerminatedNCT03267836Phase 1
- Biomarkers in Urothelial Cancer Patients Treated With PembrolizumabStatus unknownNCT03263039Phase 2
- Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLCStatus unknownNCT03262454Phase 2
- Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid TumorsCompletedNCT03261011Phase 1
- Pembrolizumab in Biliary Tract CancerCompletedNCT03260712Phase 2
- A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsCompletedNCT03260322Phase 1
- Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerActive, not recruitingNCT03257761Phase 1
- Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric CancerActive, not recruitingNCT03257163Phase 2
- Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid CancersTerminatedNCT03254732Phase 1
- Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cmStatus unknownNCT03254004Phase 2
- PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) PatientsStatus unknownNCT03251313Phase 1
- A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid TumorsCompletedNCT03248843Phase 1
- Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SDTerminatedNCT03246685Phase 2
- A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian CancerCompletedNCT03245892Phase 1
- Radiation Therapy in Combination With Durvalumab for People With Pancreatic CancerActive, not recruitingNCT03245541Phase 1/2
- Anti-platelet + Pembro for H&N TumorsCompletedNCT03245489Phase 1
- Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT03245177Phase 1
- Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3AActive, not recruitingNCT03245021Phase 1
- Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial CancerActive, not recruitingNCT03244384Phase 3
- Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP StudyActive, not recruitingNCT03244176Early Phase 1
- Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal MelanomaStatus unknownNCT03241186Phase 2
- Durvalumab in DLBCL After Autologous TransplantWithdrawnNCT03241017Phase 2
- A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 TherapyWithdrawnNCT03238638Phase 2
- Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT03237780Phase 2
- Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell LymphomaWithdrawnNCT03235869Early Phase 1
- Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for CisplatinTerminatedNCT03234153Phase 2
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal CancerActive, not recruitingNCT03233711Phase 3
- A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.Active, not recruitingNCT03233152Phase 1/2
- Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced MalignanciesActive, not recruitingNCT03233139Phase 1
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
- An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaWithdrawnNCT03227432Phase 2
- Nivolumab in Recurrent and/or Metastatic SCCHNCompletedNCT03226756Phase 2
- Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally AdvancedActive, not recruitingNCT03225664Phase 1/2
- Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast CancerTerminatedNCT03225547Phase 2
- Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung CancerActive, not recruitingNCT03223155Phase 1
- Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCCCompletedNCT03222440Not applicable
- Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)WithdrawnNCT03221634Phase 2
- Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Active, not recruitingNCT03220477Phase 1
- Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaWithdrawnNCT03220009Phase 2
- Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)Status unknownNCT03219671Phase 2
- A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsCompletedNCT03219268Phase 1
- Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCLWithdrawnNCT03212807Phase 2
- Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of PembrolizumabCompletedNCT03212651Phase 2
- A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic CancerCompletedNCT03212469Phase 1/2
- Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersActive, not recruitingNCT03212404Phase 1
- A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsCompletedNCT03203876Phase 1
- Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver CancerTerminatedNCT03203304Phase 1
- Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRCCompletedNCT03202758Phase 1/2
- Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast CancerActive, not recruitingNCT03202316Phase 2
- Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT03200587Phase 1
- An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)CompletedNCT03198130Phase 1
- A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone PlasmacytomaWithdrawnNCT03196401Phase 1
- Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck CancersTerminatedNCT03193931Phase 2
- Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine CancerCompletedNCT03192059Phase 2
- Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple MyelomaWithdrawnNCT03191981Phase 1/2
- Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell CarcinomasWithdrawnNCT03189186Phase 1
- Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal CancerCompletedNCT03187314Phase 2
- Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic CancerCompletedNCT03186326Phase 2
- The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid TumorsTerminatedNCT03182673Phase 1
- Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial CarcinomaActive, not recruitingNCT03179943Phase 2
- Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasActive, not recruitingNCT03179930Phase 2